美国放射学会与国家肾脏基金会关于肾病患者使用静脉钆基对比剂的共识声明
美国放射学会与国家肾脏基金会发布首版共识,规范肾病患者使用ACR II组或III组静脉钆基对比剂。II组对比剂在晚期肾病患者中致肾源性系统性纤维化的风险被认为极低(4931次给药零事件);仅有的III组对比剂钆塞酸二钠无混杂的肾源性系统性纤维化病例报告。应根据临床指征权衡延迟或放弃增强MRI的潜在危害与肾源性系统性纤维化风险;基于II组或III组对比剂给药,启动或调整透析可能不必要。
要点
- II组钆基对比剂在eGFR<30 mL/min/1.73 m²患者中肾源性系统性纤维化风险极低,4931次给药零事件。
- 仅有的III组对比剂钆塞酸二钠无混杂的肾源性系统性纤维化病例报告。
- 基于II组或III组对比剂给药,启动或调整透析可能不必要。
诊断标准与关键数值
- II组钆基对比剂用于eGFR<30 mL/min/1.73 m²患者:4931次给药后肾源性系统性纤维化零事件,95%CI上限总体0.07%、5D期慢性肾脏病0.2%、5期慢性肾脏病未透析0.5%。
- 仅有的III组对比剂钆塞酸二钠:无混杂的肾源性系统性纤维化病例报告。
临床应用与阅片要点
- 对急性肾损伤或eGFR<30 mL/min/1.73 m²患者,应根据临床指征权衡延迟或放弃II组或III组钆基对比剂增强MRI的潜在危害与肾源性系统性纤维化风险,前者可能大于后者。
- 基于II组或III组钆基对比剂给药,启动或调整透析可能不必要。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Inaugural consensus statements were developed and endorsed by the American College of Radiology (ACR) and National Kidney Foundation to improve and standardize the care of patients with kidney disease who have indication(s) to receive ACR-designated group II or group III intravenous gadolinium-based contrast media (GBCM). The risk of nephrogenic systemic fibrosis (NSF) from group II GBCM in patients with advanced kidney disease is thought to be very low (zero events following 4931 administrations to patients with estimated glomerular filtration rate [eGFR] <30 mL/min per 1.73 m2; upper bounds of the 95% confidence intervals: 0.07% overall, 0.2% for stage 5D chronic kidney disease [CKD], 0.5% for stage 5 CKD and no dialysis). No unconfounded cases of NSF have been reported for the only available group III GBCM (gadoxetate disodium). Depending on the clinical indication, the potential harms of delaying or withholding group II or group III GBCM for an MRI in a patient with acute kidney injury or eGFR less than 30 mL/min per 1.73 m2 should be balanced against and may outweigh the risk of NSF. Dialysis initiation or alteration is likely unnecessary based on group II or group III GBCM administration.
引用
- Weinreb JC, Rodby RA, Yee J, et al. Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Kidney Med. 2020. PMID: 33604544. doi:10.1016/j.xkme.2020.10.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。